|
Press Releases:
September
11, 2006 - AuRx announces the termination of its technology
license agreement with Landsteiner Scientific of Mexico City, Mexico
Aug 31, 2004 - Tentative
approval by the Mexican Ministry of Health to conduct Phase 3 Trials
June 6, 2004 -Deadline Extended!
***Link Broken*** This link will take you to the
Sept 11, 2006 press release
March 2, 2004 -Open letter to herpes sufferers
February 12, 2004 -AuRx, Inc. is seeking volunteers who
are currently infected with HSV-2 to participate in a clinical trial
registry.
February 12, 2004 - AuRx tests
in nude mice show its recombinant therapy does not cause disease
in immune compromised animals.
February 10, 2004 - AuRx announces completion of collection
of one year data in its Phase I/II clinical trial.
February 2, 2004 - AuRx announces publication of the evaluation
of its diagnostic technology for the determination of the presence
of infection with HSV2.
November 19, 2002
- Dr J.W.Burnett presents
one year results of Phase I/II trial at the Bereston Memorial Lecture
of the Maryland Dermatologic Society.
November 11, 2002 -
Dr J.W.Burnett to present
one year results of Phase I/II trial at the Bereston Memorial Lecture
of the Maryland Dermatologic Society, November 19, 2002.
October 11, 2002 - AuRx,
Inc., Announces publication of the successful results of the clinical
evaluation of its therapeutic vaccine for genital herpes.
|
